Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

An international study led by researchers at Oxford University Hospitals NHS Foundation Trust has shown that patients with cirrhosis are at increased risk of dying as a result of COVID-19.

Patient with cannula in their hand © Anna Shvets via Pexels

The study, published in the Journal of Hepatology, found that mortality from COVID-19 was particularly high among patients with more advanced cirrhosis (called Childs-Pugh B or C cirrhosis) and those with alcohol-related liver disease.

The study, which received support from the NIHR Oxford Biomedical Research Centre, was a collaboration between scientists at the Oxford Liver Unit, based at Oxford’s John Radcliffe Hospital, and colleagues at the University of North Carolina (USA), and was supported by the European Association for the Study of the Liver (EASL)

The paper presented data on over 1,300 patients from 29 different countries and compared COVID-19 outcomes between patients with and without liver disease.

The full story is available on the NIHR Oxford Biomedical Research Centre website